| Announcement of the Ministry of Commerce of the People's Republic of China | | 中华人民共和国商务部公告 |
| (No.91 [2018]) | | （2018年第91号） |
| Announcement on Filing of Countervailing Investigation against Imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic Acidpmethoxybenzyl Ester Originating in India | | 关于对原产于印度的进口7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯进行反补贴立案调查的公告 |
| The Ministry of Commerce of the People's Republic of China (hereinafter referred to as the “MOFCOM” or the "Ministry of Commerce") received, on October 10, 2018, a written petition for countervailing investigation formally submitted by Ningbo Renjian Pharmaceutical Co., Ltd. (hereinafter referred to as “the Applicant”) on behalf of domestic industry of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester, in which the Applicant requested a countervailing investigation to be conducted against imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester originating in India. According to Article 16 of the Countervailing Regulations of the People's Republic of China, on October 30, 2018, the MOFCOM invited the Indian government for discussion on matters related to the countervailing investigation. The Indian government submitted written comments on November 16, 2018. | | 中华人民共和国商务部（以下简称商务部）于2018年10月10日收到宁波人健化学制药有限公司（以下称申请人）代表国内7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯产业正式提交的反补贴调查申请，申请人请求对原产于印度的进口7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯进行反补贴调查。根据《中华人民共和国反补贴条例》第十六条规定，2018年10月30日，商务部就有关反补贴调查事项向印度政府发出磋商邀请。印度政府于2018年11月16日提交了书面评论意见。 |
| In accordance with relevant provisions of the Countervailing Regulations of the People's Republic of China, the MOFCOM conducted an investigation into the qualification of the Applicant, relevant situations of the products in question and the products of the same kind in China, impact of the imported products on domestic industry and the relevant situations of countries (regions) involved. | | 商务部依据《中华人民共和国反补贴条例》有关规定，对申请人的资格、申请调查产品的有关情况、中国同类产品的有关情况、申请调查产品对国内产业的影响、申请调查国家（地区）的有关情况等进行了审查。 |
| According to the evidence provided by the Applicant and the preliminary review of the Ministry of Commerce, the total output of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester of the Applicant in 2015, 2016 and 2017 accounts for more than 50% of that of the same kind in China, and therefore the provisions of Article 11 and Article 13 of the Countervailing Regulations of the People's Republic of China on applying by domestic industry for countervailing investigation are met. | | 根据申请人提供的证据和商务部的初步审查，申请人的7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯产量在2015年、2016年和2017年均占同期中国同类产品总产量的50%以上，符合《中华人民共和国反补贴条例》第十一条和第十三条有关国内产业提出反补贴调查申请的规定。 |
| Name of the Product under Investigation: imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester In the meanwhile, it is claimed in the petition, that the products entering into Chinese market soar with price going up after price decline, and therefore cut down the prices of similar products in the domestic market, thus leading to lower market share, decline of the output, rate of operation and pretax profit as a whole, and substantial damages to domestic industry. Moreover, there are causal links between the subsidies granted to the underlying products and the substantive injuries suffered by the domestic industry. Upon review, the MOFCOM believes that the application contains the contents and relevant evidence as required in Article 14 and Article 15 of the Countervailing Regulations of the People's Republic of China for a countervailing investigation. | | 申请书主张，申请调查产品接受了印度政府的补贴，印度7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯产业（企业）可能受益的补贴项目共计20项。申请书同时主张，申请调查产品进入中国市场数量大幅增长，进口价格先降后升，对国内产业同类产品价格造成削减和抑制，导致国内产业市场份额减少，产量、开工率、税前利润下降，国内产业遭受了实质损害，且申请调查产品所接受的补贴与国内产业实质损害存在因果关系。经审查，商务部认为申请书中包含了《中华人民共和国反补贴条例》第十四条、第十五条规定的反补贴调查立案所要求的内容及有关证据。 |
| As per the above-mentioned results, the MOFCOM decides, according to Article 16 of the Countervailing Regulations of the People's Republic of China, to file countervailing investigation against imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester originating in India as of November 26, 2018. Relevant matters are hereby announced as follows: | | 根据上述审查结果，依据《中华人民共和国反补贴条例》第十六条的规定，商务部决定自2018年11月26日起对原产于印度的进口7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯进行反补贴立案调查。现将有关事项公告如下： |
| I. Filing of Investigation and Investigation Period | | |
| As of the issue date hereof, the MOFCOM files a countervailing investigation against imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester originating in India. The countervailing investigation period determined upon the examination is from October 1, 2017 to September 30, 2018, and the investigation period for industrial damages is from January 1, 2015 to September 30, 2018. | | 一、立案调查及调查期 |
| II. Products under Investigation and Scope of Investigation | | 自本公告发布之日起，商务部对原产于印度的进口7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯进行反补贴立案调查，本次调查确定的补贴调查期为2017年10月1日至2018年9月30日，产业损害调查期为2015年1月1日至2018年9月30日。 |
| Scope of investigation: imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester originating in India. | | |
| Name of the Product under Investigation: imports of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester. | | 二、被调查产品及调查范围 |
| Name in English: | | 调查范围：原产于印度的进口7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯。 |
7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acidpmethoxybenzyl ester
．．．．．． | | 被调查产品名称：7-苯乙酰氨基-3-氯甲基-4-头孢烷酸对甲氧基苄酯。
．．．．．． |
|
Dear visitor, as a premium member of this database, you will get complete access to all content.Please go premium and get more.
1. To become a premium member, please call 400-810-8266 Ext. 171.
2. Binding to the account with access to this database.
3. Apply for a trial account.
4. To get instant access to a document, you can Pay Amount 【￥500.00】 for your single purchase. | |
您好：您现在要进入的是北大法宝英文库会员专区。
如您是我们英文用户可直接 登录，进入会员专区查询您所需要的信息；如您还不是我们 的英文用户；您可通过网上支付进行单篇购买，支付成功后即可立即查看本篇内容。
Tel: +86 (10) 82689699, +86 (10) 82668266 ext. 153
Mobile: +86 13311570713
Fax: +86 (10) 82668268
E-mail:info@chinalawinfo.com
|
| | | |
| | | |